MERRIMACK PHARMACEUTICALS IN's ticker is MACKXXXX and the CUSIP is 590328100. A total of 139 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q4 2015. The put-call ratio across all filers is 1.51 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $31,000 | -59.7% | 25,000 | 0.0% | 0.00% | -50.0% |
| Q1 2017 | $77,000 | -24.5% | 25,000 | 0.0% | 0.00% | -33.3% |
| Q4 2016 | $102,000 | -35.8% | 25,000 | 0.0% | 0.00% | -25.0% |
| Q3 2016 | $159,000 | +17.8% | 25,000 | 0.0% | 0.00% | +33.3% |
| Q2 2016 | $135,000 | -35.4% | 25,000 | 0.0% | 0.00% | -40.0% |
| Q1 2016 | $209,000 | +5.6% | 25,000 | 0.0% | 0.01% | +25.0% |
| Q4 2015 | $198,000 | -7.0% | 25,000 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $213,000 | -9.4% | 25,000 | +31.6% | 0.00% | +33.3% |
| Q2 2015 | $235,000 | +4.0% | 19,000 | 0.0% | 0.00% | 0.0% |
| Q1 2015 | $226,000 | +66.2% | 19,000 | +58.3% | 0.00% | +50.0% |
| Q4 2014 | $136,000 | +29.5% | 12,000 | 0.0% | 0.00% | +100.0% |
| Q3 2014 | $105,000 | +20.7% | 12,000 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $87,000 | +45.0% | 12,000 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $60,000 | – | 12,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 5,000,000 | $20,400,000 | 4.19% |
| Consonance Capital Management LP | 9,067,998 | $36,997,000 | 4.06% |
| Lagoda Investment Management, L.P. | 1,522,529 | $6,212,000 | 2.13% |
| INDUS CAPITAL PARTNERS, LLC | 1,050,000 | $4,284,000 | 0.56% |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 9,072,877 | $37,017,000 | 0.32% |
| GARRISON BRADFORD & ASSOCIATES INC | 77,700 | $317,000 | 0.29% |
| Cannell & Co. | 1,572,978 | $6,418,000 | 0.23% |
| Virtus ETF Advisers LLC | 179,625 | $733,000 | 0.22% |
| LeJeune Puetz Investment Counsel LLC | 3,976 | $161,000 | 0.12% |
| STONERIDGE INVESTMENT PARTNERS LLC | 221,838 | $905,000 | 0.12% |